|
Europe Patent Law News is an EIN News Service for patents and trademarks professionals. Constantly updated news and information about Europe Patents & Trademarks.
Latest Europe Patent Law News
- DSM Pharmaceutical Products Forms Manufacturing Alliance With Galenix 7 Nov 2009 08:11 GMT
... as its extensive know-how and experience in patented, innovative drug delivery system design and drug ... a global provider of high quality custom contract manufacturing and development services to the pharmaceutical ... in this press release, unless required by law. CONTACT: DSM Pharmaceutical Products, Guy Tiene, Director ...
- European patent office to study green innovation 6 Nov 2009 07:54 GMT
... difficult to quantify the true extent of Europe's eco-innovation sector. This will change in April ... project looking at the growth in new patents for environmentally sound technologies. The study will ... by adding that the EU can only act where Community intervention adds real value. The ...
- Crucell Announces Third Quarter 2009 Results 6 Nov 2009 14:37 GMT
... one of the largest vaccine markets in Europe. * Detailed positive results of the Phase ... due strong sales of Epaxal®, despite the impact of reduced travel from the economic crisis. ... Crucell was granted a total of 22 patents, including patents for: * Monoclonal antibodies against ...
- Labopharm Reports Results for Third Quarter Fiscal 2009 / - Company Advances Plans to Realize the Benefits of Commercialization: Streamlines Operations to Focus on Nearer-Term Commercial Opportunities - 6 Nov 2009 13:55 GMT
... the Company's share of litigation costs for patent enforcement related to its once-daily tramadol product ... Company a new Prescription Drug User Fee Act (PDUFA) action date of February 11, 2010. ... these forward-looking statements. Except as required by law, the Company undertakes no obligation and does ...
- Labopharm Reports Results for Third Quarter Fiscal 2009 6 Nov 2009 14:17 GMT
... the Company's share of litigation costs for patent enforcement related to its once-daily tramadol product ... Company a new Prescription Drug User Fee Act (PDUFA) action date of February 11, 2010. ... these forward-looking statements. Except as required by law, the Company undertakes no obligation and does ...
- BUYINS.NET: CGV, RPRX, CWCO, NEXM, KDE, CNTY Expected To Be Lower Leading Up To Next Earnings Releases 6 Nov 2009 10:44 GMT
... indicator that predicts how a stock will act before its earnings are released. The specific ... to customers in North America, South America, Europe, Africa, the Middle East, and the Asia ... and function. In addition, it holds a patent portfolio of phentolamine-based product candidates, including VASOMAX ...
- InterMune Reports Third Quarter 2009 Financial Results and Business Highlights 6 Nov 2009 13:32 GMT
... regulatory authorities in the United States and Europe, respectively." Results for the Three Months Ended ... of section 21E of the Securities Exchange Act of 1934, as amended, that reflect InterMune's ... is able to obtain, maintain and enforce patents and other intellectual property; (v) risks related ...
- www.StockMarketingInc.com: Breaking News!! JMBA,PLUS,JBLU,NUVA,RAIL,RAND Sign Up Now!! 6 Nov 2009 18:37 GMT
... services, flexible lease financing, proprietary software, and patented business methods. Founded in 1990, ePlus has ... Executive Vice Presidents for both Asia and Europe that will report to Keith Valentine, President ... defined under the Private Securities Litigation Reform Act of 1995. Forward-looking statements represent our estimates ...
- DSM Pharmaceutical Products forms... 6 Nov 2009 14:51 GMT
... as its extensive know-how and experience in patented, innovative drug delivery system design and drug ... a global provider of high quality custom contract manufacturing and development services to the pharmaceutical ... in this press release, unless required by law. ...
- XOMA Granted First European Patent Covering XOMA 052 4 Nov 2009 13:33 GMT
... XOMA Granted First European Patent Covering XOMA 052 XOMA Granted First European ... XOMA 052. The patent provides exclusivity in Europe into 2026. IL-1 beta is a pro-inflammatory ... meaning of Section 27A of the Securities Act of 1933 and Section 21E of the ...
- Beckman Coulter Announces Third Quarter 2009 Results 2 Nov 2009 17:35 GMT
... in constant currency) Revenue(2) 11.6% 3.8% ODS impact 8.8% 2.9% Recurring Revenue(2) 17.3% 10.0% ODS ... update these disclosures except as required by law. Change in Accounting for Convertible Debt Securities ... sublicense rights to obtain rights under certain patents to be used to develop a molecular ...
- Human Genome Sciences and GlaxoSmithKline Announce Positive Results in Second of Two Phase 3 Trials of BENLYSTA in Systemic Lupus Erythematosus 2 Nov 2009 12:34 GMT
... with regulatory authorities in the United States, Europe and other regions. We will continue to ... meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E ... with facilities, intense competition, the uncertainty of patent and intellectual property protection, Human Genome Sciences' ...
- Human Genome Sciences and GlaxoSmithKline Announce Positive Results in Second of Two Phase 3 Trials of BENLYSTA'˘ in Systemic Lupus Erythematosus 2 Nov 2009 05:31 GMT
... with regulatory authorities in the United States, Europe and other regions. We will continue to ... meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E ... with facilities, intense competition, the uncertainty of patent and intellectual property protection, Human Genome Sciences' ...
- Human Genome Sciences and GlaxoSmithKline Announce Positive Results in Second of Two Phase 3 Trials of BENLYSTA in Syst 2 Nov 2009 05:31 GMT
... with regulatory authorities in the United States, Europe and other regions. We will continue to ... meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E ... with facilities, intense competition, the uncertainty of patent and intellectual property protection, Human Genome Sciences' ...
- Human Genome Sciences and GlaxoSmithKline Announce Positive Results in Second of Two Phase 3 Trials of belimumab in Systemic Lupus Erythematosus 2 Nov 2009 05:52 GMT
... with regulatory authorities in the United States, Europe and other regions. We will continue to ... meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E ... with facilities, intense competition, the uncertainty of patent and intellectual property protection, Human Genome Sciences’ ...
Powered by 
Europe Patents News Sections
These stories are not published by IPD Group, Inc. and these links will take you to other websites. Some of these websites require their own registration to read their stories.
<<< Please read the disclaimer for more details.>>> | |
Patents & Trademarks Today
|
a digital news provider
unwiredview.com:
courthousenews.com:
examiner.com:
thanhniennews.com:
guardian.co.uk:
macworld.co.uk: